Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase II trial

Immunotherapy combined with chemotherapy has been demonstrated to be effective in early triple-negative breast cancer (TNBC). In this single-arm, phase II study with Simon’s two-stage design, we investigated the efficacy and safety of neoadjuvant camrelizumab plus chemotherapy in patients with early...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chengzheng, Liu, Zhenzhen, Chen, Xiuchun, Qiao, Jianghua, Lu, Zhenduo, Li, Lianfang, Sun, Xianfu, Zhang, Chongjian, Yue, Xiayu, Xia, Qingxin, Zhang, He, Yan, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10589334/
https://www.ncbi.nlm.nih.gov/pubmed/37863916
http://dx.doi.org/10.1038/s41467-023-42479-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10589334/
https://www.ncbi.nlm.nih.gov/pubmed/37863916
http://dx.doi.org/10.1038/s41467-023-42479-w

Ejemplares similares